Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, InSilico Medicine is raising $95,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Alex Zhavoronkov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About InSilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Belgium, Russia, UK, Taiwan, and China sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinsons Disease, Alzheimers Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

To learn more about InSilico Medicine, visit http://insilico.com/

Contact:
Alex Zhavoronkov, Chief Executive Officer
410-710-9674
alex@insilico.com
https://www.linkedin.com/in/zhavoronkov/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved